Risk stratification of IBD-associated liver disease using routinely collected biomarkers from a large-scale real-world dataset
Real-world biomarker data can support early risk stratification for IBDALD. Elevated ALT and ALP at IBD diagnosis and distinct longitudinal trajectories highlight the need for follow-up to biomarker normalisation, with persistent abnormalities prompting earlier hepatobiliary investigation to reduce diagnostic delay and improve outcomes.
Authors
- Sarah Ennis (ORCID: https://orcid.org/0000-0003-2648-0869)
- Zachary Green (ORCID: https://orcid.org/0000-0002-2907-5538)
- James John Ashton (ORCID: https://orcid.org/0000-0003-0348-8198)
- R Mark Beattie (ORCID: https://orcid.org/0000-0003-4721-0577)
- Gabriela Czanner (ORCID: https://orcid.org/0000-0002-1157-2093)
- Alexandre Zacharie Kadhim (ORCID: https://orcid.org/0000-0001-5600-0411)
- Lynn Win
Institutions
- NIHR Southampton Biomedical Research Centre (GB)
- Southampton Children's Hospital (GB)
- University of Southampton (GB)
Publication Details
- Journal
- BMJ Open Gastroenterology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/bmjgast-2025-002028
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- University of Southampton
- National Institute for Health Research Southampton Biomedical Research Centre
- Engineering and Physical Sciences Research Council